Kidswell Bio Corporation
4584・Growth Market・Pharmaceuticals
Governance
The company has a Board of Corporate Auditors and 4 directors (including 2 outside directors, 50% outside ratio), and has introduced an executive officer system to separate supervision and execution. All directors achieved a 100% attendance rate at Board meetings (15/15 sessions), and the 2 outside directors are designated as independent officers under Tokyo Stock Exchange rules.
Risk Management
The company has established a risk management framework based on its Risk Management Regulations and Risk & Compliance Committee, and has also developed emergency response implementation guidelines. Through advisory agreements with law firms and international patent firms, it has secured a system capable of addressing legal risks related to contracts and intellectual property, among others.
Shareholder Returns
Currently continuing to pay no dividend. Annual dividend of ¥0 for both FY2025 (ending March 2025) and FY2026 (ending March 2026). No dividend is forecast for FY2027 (ending March 2027) either. The policy is to reinvest profits generated by the biosimilar business into research and development for the cell therapy business, prioritizing the stable achievement of consolidated operating profitability.
Dividend Policy
Annual dividend of ¥0 (no dividend) for both FY2025 (ending March 2025) and FY2026 (ending March 2026). No dividend is also forecast for FY2027 (ending March 2027). The company's management goal is to reinvest the continuous profits generated by the biosimilar business into research and development for the cell therapy business (regenerative medicine), thereby stably achieving consolidated operating profitability. While returning profits to shareholders is regarded as an important issue, the current policy is to prioritize strengthening the financial base through retained earnings and reinvestment in R&D activities.
ESG
The Company has not yet formulated a basic policy on sustainability, and no specific indicators or targets have been disclosed. However, it is engaged in human capital initiatives such as securing and developing biotechnology talent, respecting diversity, and establishing flexible work arrangements. ESG governance is operated in an integrated manner with the existing corporate governance framework, and the Company states that it is considering formulating a basic policy going forward.
Last updated: June 29, 2026